Tong Ren Tang Technologies Co (1666) AI Stock Analysis

• Market Cap: $6.56B
• Dividend Yield: 3.88%
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): 11.6
• Beta (1Y): 0.85
• Revenue Growth: 4.70%
• EPS Growth: -13.82%
• Country: HK
• Employees: 3,991
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.44
• Shares Outstanding: 628,704,000
• 10 Day Avg. Volume: 1,052,058
• 30 Day Avg. Volume: 1,090,952
• PEG Ratio: -0.56
• Price to Book (P/B): 0.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: ―

Tong Ren Tang Technologies Co shows strong financial health with solid revenue growth and a stable balance sheet; however, declining profitability and cash flow concerns weigh on the score. Technical analysis indicates a neutral outlook, while the attractive valuation could provide support. The absence of recent earnings call data or notable corporate events leaves earnings growth and strategic direction uncertain.

Tong Ren Tang Technologies Co Business Overview & Revenue Model

Company Description

Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicine products in Mainland China and Hong Kong. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, and foot care products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, cosmetics, and healthcare products; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food and daily chemical products, and medical services. The company was founded in 1669 and is based in Beijing, the People's Republic of China.

How the Company Makes Money

Tong Ren Tang Technologies Co. makes money primarily through the manufacturing and sale of its traditional Chinese medicine products. The company's revenue streams include direct sales to consumers through its extensive retail network, sales to hospitals and clinics, and export sales in international markets. Key revenue drivers include its well-established brand reputation, a broad portfolio of TCM products, and strategic partnerships with healthcare providers and distributors. The company also benefits from the growing global interest in alternative and traditional medicine, which expands its market reach and potential customer base.

Tong Ren Tang Technologies Co Financial Statement Overview

Summary

Tong Ren Tang Technologies Co is in good financial health, with strong revenue growth and a solid balance sheet. However, declining net profit margins and lack of recent cash flow data could pose future challenges. The company should address profitability and cash flow management to maintain its financial stability.

Income Statement

Tong Ren Tang Technologies Co has demonstrated a strong revenue growth trend over the years, with a 7.17% increase from 2022 to 2023 and a 7.18% increase from 2023 to 2024. The Gross Profit Margin for 2024 is approximately 39.64%, which is robust for the industry. However, the Net Profit Margin decreased from 8.71% in 2023 to 7.19% in 2024, indicating a decline in profitability. EBIT and EBITDA margins are stable, suggesting operational efficiency.

Balance Sheet

The company maintains a strong financial position with a Debt-to-Equity Ratio of 0.34 in 2024, indicating low leverage and financial stability. The Return on Equity (ROE) for 2024 stands at 7.24%, which is reasonable. The Equity Ratio is high at 50%, reflecting a solid capital structure with a significant portion of assets funded by equity.

Cash Flow

The Cash Flow statement shows inconsistency, with no Free Cash Flow reported for 2024, which may indicate cash management issues. Historically, Operating Cash Flow has been positive, but the lack of data for 2024 raises concerns. The company should focus on ensuring consistent cash flow to support operations and growth.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.26B	6.77B	5.99B	5.40B	4.61B
	Gross Profit
2.88B	2.85B	2.59B	2.29B	2.07B
	EBIT
985.16M	1.12B	1.21B	1.08B	943.55M
	EBITDA
1.17B	1.30B	1.39B	1.26B	1.14B
	Net Income Common Stockholders
521.79M	590.19M	582.89M	507.25M	467.55M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.38B	4.24B	4.18B	3.89B	3.49B
	Total Assets
14.41B	13.51B	12.48B	11.59B	10.94B
	Total Debt
2.43B	1.63B	1.59B	1.64B	1.69B
	Net Debt
-1.70B	-1.12B	-2.13B	-1.60B	-1.26B
	Total Liabilities
4.24B	3.86B	3.47B	3.44B	3.19B
	Stockholders Equity
7.21B	6.89B	6.48B	5.98B	5.73B
Cash Flow		Free Cash Flow
-158.56M	450.78M	565.85M	877.01M	-110.09M
	Operating Cash Flow
15.61M	554.17M	723.77M	1.03B	435.81M
	Investing Cash Flow
0.00	-1.07B	43.01M	-197.36M	-195.44M
	Financing Cash Flow
288.35M	-497.76M	-499.45M	-474.67M	-164.51M

Tong Ren Tang Technologies Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1666, the sentiment is Positive. The current price of 5.2 is above the 20-day moving average (MA) of 5.08, above the 50-day MA of 4.91, and above the 200-day MA of 5.03, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 64.79 is Neutral, neither overbought nor oversold. The STOCH value of 84.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1666.

Tong Ren Tang Technologies Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1666	69 Neutral	$6.56B	11.59	7.39%	3.88%	4.70%	-13.82%
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
BJTRF		$907.72M	8.46	12.58%	6.51%	―	―
CHIZF		$1.40B	159.33	0.25%	―	―	―
2877	77 Outperform	HK$5.65B	6.20	11.61%	7.77%	-18.09%	-15.08%
2256	65 Neutral	HK$6.52B	163.37	1.43%	―	2433.62%	―
0723		HK$159.70M	―	-3.92%	―	―	―

Tong Ren Tang Technologies Co Corporate Events

Tong Ren Tang Technologies Reports Strong Q1 2025 Financial Results

Tong Ren Tang Technologies Co. Ltd. announced its unaudited financial results for the first quarter of 2025, reporting an operating revenue of approximately RMB2,035.42 million and a net profit of RMB227.23 million. The announcement highlights the company’s financial stability and growth potential, reinforcing its strong position in the traditional Chinese medicine industry.

Tong Ren Tang Technologies Expands Global Reach Through Strategic Partnership

Tong Ren Tang Technologies Co. Ltd. announced that its subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited, has entered into a strategic cooperation agreement with China Duty Free International Limited. This agreement aims to leverage both parties’ strengths to expand Tong Ren Tang’s overseas markets, focusing on innovative business models and exclusive product versions. The collaboration will enhance the company’s market positioning by integrating resources and exploring multi-dimensional cooperation in business, products, and culture, particularly in the Chinese health food and beverage sector.

Tong Ren Tang Technologies Declares Final Dividend for 2024

Tong Ren Tang Technologies Co. Ltd. has announced a final cash dividend of RMB 0.18 per share for the financial year ending December 31, 2024, with a payment date set for August 11, 2025. The announcement includes details on withholding tax rates for different categories of shareholders, highlighting a 10% rate for non-resident enterprises and individuals, and a 20% rate for those investing through the Shenzhen-Hong Kong Stock Connect. This dividend declaration reflects the company’s ongoing commitment to returning value to its shareholders, potentially enhancing its market position and investor confidence.

Tong Ren Tang Reports Revenue Growth Amid Profit Decline in 2024

Tong Ren Tang Technologies Co. Ltd. reported its annual results for 2024, showing a revenue increase of 7.18% to RMB7.26 billion, despite a net profit decline of 10.62% to RMB886.93 million. The company faced challenges due to rising raw material costs and declining sales in the Chinese medicine industry but responded by adjusting marketing strategies and optimizing operations to enhance market competitiveness.

Tong Ren Tang Expands Market Reach with New Medicine Registration in Hong Kong

Tong Ren Tang Technologies Co. Ltd. announced that its subsidiary, Beijing Tong Ren Tang Chinese Medicine Company Limited, has received the Certificate of Registration for its proprietary medicine, Jin Chai Shi Hu San, from the Chinese Medicine Council of Hong Kong. This certification allows the product to be sold in Hong Kong, aiding in the expansion of the company’s product lines and market reach. Although the registration is a positive step for market expansion, it is not expected to have a significant immediate impact on the company’s operations or financial performance. The company advises caution due to potential influences from policy changes, exchange rates, and market competition.

Tong Ren Tang Technologies Schedules Board Meeting to Discuss Financial Results and Dividend

Tong Ren Tang Technologies Co. Ltd. has announced a board meeting scheduled for March 28, 2025, to discuss several key financial and operational matters. The agenda includes approving the audited consolidated results for the year ending December 31, 2024, considering the recommendation of a final dividend, and potentially closing the register of members, which could have implications for shareholders and market positioning.